NewsHK

BTIG terminates $50 million ATM sales agreement with Matinas BioPharma (MTNB)

7/25/2026

Against the backdrop of a capital environment that continues to test smaller biotech issuers, BTIG, LLC terminated its at-the-market sales arrangement with Matinas BioPharma Holdings, Inc.

(NYSE American: MTNB) on July 23, 2026.

The broker-dealer invoked Section 12(a) of the Sales Agreement to close out the facility with immediate effect, removing a capital mechanism the Bedminster, New Jersey company had held in reserve since July 2020.

No replacement arrangement was disclosed.

Keep reading

Read the full story

Open on NewsHK